KT&G Life Sciences Overview

  • Founded
  • 2002
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 30
Employees
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 2

KT&G Life Sciences General Information

Description

Developer of medicines and drugs. The company is researching drugs for treating Cancer, Obesity, Type-2 Diabetes, Liver Disease, MELAS Syndrome, Dry Eye Syndrome, Atopic Dermatitis and other metabolic diseases.

Contact Information

Website
www.ktnglifesciences.com
Formerly Known As
Mazence
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Acquirer
Yungjin Pharmaceutical
Primary Office
  • B-1004-6 Digital Empire Building 16
  • Deogyang-daero 1556 beon-gil Yeongtong-gu
  • Suwon-si, Gyeonggi-do 443-702
  • South Korea
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

KT&G Life Sciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore KT&G Life Sciences‘s full profile, request access.

Request a free trial

KT&G Life Sciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

KT&G Life Sciences Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore KT&G Life Sciences‘s full profile, request access.

Request a free trial